Over the 20th century, the U.S. developed norms that separated the justice system from the whims of the president. Trump is breaking that down and weakening the United States as a strong democracy.
“A federal judge has paused the Trump administration’s plan to lay off more than 500 employees of the U.S. Agency for Global Media — most from Voice of America — while warning that senior officials there had repeatedly failed to comply with his orders to preserve the international broadcaster’s key operations.”
“Natcast signed on 200 members — notably, Nvidia, Intel, Apple, Samsung, Google and AMD — to pursue breakthroughs in the foundational technology that powers virtually every modern asset from AI to defense systems. The group spent its year-and-a-half existence trying to set up and eventually run a national hub where that R&D would happen, along with programs to ease the semiconductor industry’s severe talent crunch.
Lutnick’s clawback produced deep uncertainty while companies, researchers and lawmakers scrambled to understand where it leaves over a dozen awardees, plus the remaining billions. Nearly $2 billion was promised to infrastructure, research and workforce projects in states like Arizona, New York, California and Texas.
…
The Commerce head has focused its dealmaking heavily on chipmakers. His new “investment accelerator” was handed supervision of tens of billions of dollars in CHIPS subsidies and ordered to negotiate “much better deals than those of the previous administration.” The undermining of Natcast followed an agreement to grant the U.S. a 10 percent stake in Intel, when Lutnick redid the terms of its CHIPS award.
Seven people, including from three Capitol Hill offices, raised concerns with the possibility that renegotiations for this $7.4 billion may involve similar government equity stakes. People also questioned whether requirements to share revenue from research patents could be under consideration. Lutnick spoke about subjecting universities to the idea the day after he voided the Natcast contract.
…
When the agency started soliciting proposals for R&D funding last week, it told applicants, as a condition of an award, they “may be required to issue to the Department equity, warrants, licenses to intellectual property, royalties or revenue sharing, or other such instruments to ensure a return on investment.” The guidelines do not mention the national hub, yet cite the law that established it.
LC: If we need these companies to produce important technology, then we don’t need special deals to help them. We should help them because it is good for the country. The technology will produce a better economy and therefore more normal tax revenue. If we want these companies to pay us back directly, just make sure they are paying their normal taxes.
…
“They decided to burn two years of delay to try to create their own thing,” said a former Trump official, who, like several others for this report, was granted anonymity to discuss a sensitive topic. “While Natcast was not a Republican initiative and wasn’t how we wanted it go, I think it was better than burning down the whole system and starting over again.”
…
“The companies are scared,” said a person familiar with the industry dynamics. “Companies want CHIPS funding, and they’re very afraid that if they speak out, they’ll lose it. No one wants to come into the crosshairs of the administration.”
…
“There’s just a feeling of, for many of us, a year’s work going down the tubes, taxpayer dollars being flushed down the toilet,” said one person closely associated with Natcast.”
…
An industry lobbyist said, “those who stand to lose the most in this process will be start-ups and research centers that were at the cutting edge of innovation.””
“President Donald Trump is ratcheting up pressure on Republicans to redraw congressional maps across the country, going as far as weighing a primary challenge to New Hampshire Gov. Kelly Ayotte if she continues avoiding a remapping effort in her state.”
“President Donald Trump has struck a multi-pronged deal with pharmaceutical giant Pfizer to lower the price of some of the company’s medicines, while clearing a path for the drugmaker to receive a three-year reprieve from certain tariffs.
The drugmaker will participate in a new direct purchasing platform named TrumpRx.gov that will let American patients buy a “large majority” of its primary care treatments and “some select specialty brands” at a discount. Those drugs will be offered at “savings that will range as high as 85% and on average 50%,” Pfizer said in a press release Tuesday.”